ELEVĒO
ZOOM International a worldwide leader in omni-channel compliance recording, workforce optimization (WFO), and revenue protection software for contact centers will begin doing business solely as elevēo beginning June 2nd , 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005093/en/
For over 20 years, ZOOM International has been a leading workforce optimization software provider in the contact center industry. Very early on, we were approached to solve a compliance problem with call recording. We built a creative software solution in record time, and began a journey crossing continents, employing hundreds of colleagues, and eventually improving operations, compliance, and customer experience for thousands of customers in 94 countries via more than 550 channel partners in the communications industry.
Over time we have earned an 88 NPS score from ZOOM International customers & partners for our world-class support and innovative WFO products. We believe this is a direct result of our core purpose; to create great customer experiences and serve the needs of others: employees, partners & end users. The ZOOM International brand has served us well.
So, why change brands now? As with all strategic business initiatives, there are many reasons, but here are the most impactful:
- Our software platform strategy has culminated in a new native cloud foundation for our products, opening-up new services, products, pricing, and subscription models. With new, improved platform and product capabilities, we felt it deserved a fresh name and look.
- Moreover, we are dedicated to constant improvement. Our mission is to elevate every encounter, which directly focuses on elevating employee engagement, elevating the customer experience and of course increasing the efficiency of each and every channel interaction with a distinct focus on compliance.
The company we created 20 years ago is a very different company than we are today. We are adapting to new business and market needs, serving a broader audience, and migrating to a subscription & cloud native focused strategy.
Effective June 2nd, 2020 ZOOM International will begin solely doing business under the elevēo brand name. All ZOOM International manufactured software products, and solutions (including OEMs) will be developed, marketed, sold, and supported under the elevēo name. In addition to the name, we will be launching a new software as a service offering the week of August 17th, that we call elevēo as a service which allows customers to subscribe to elevēo products without the burden of hosting them and with lower upfront cost.
Perhaps the reasons are best said from our CEO Brian Shore: “We are delighted to announce our new name and brand – Eleveo! Eleveo is closely connected to the Latin word elevo which translates to lift up or to raise. When we think about our mission and how we genuinely wish to serve others. When we think about our products and solutions and the problems we solve. We felt Eleveo in one word universally defines our brand, our culture and our passion to serve others!”
While our name has changed, our culture will not! Serving the needs of others and elevating every encounter is our brand promise! We will continue to innovate, offer greater flexibility, and do business your way as elevēo.
ABOUT ZOOM International
ZOOM guides contact centers toward increased revenue and decreased customer attrition by elevating every customer encounter. Our software captures customer sentiment, providing a true north to guide contact centers in the measurement of people, processes, technologies and assets.
To date ZOOM has helped over 2200 customers and partners worldwide, ranging from sub-100 agent contact centers to brands like Amerigas, IBM, Homecredit, Finansbank, Tata Sky, Generali, Allianz, and Vodafone spanning 90 Countries. More information can be found at zoomint.com or on Twitter @zoomint .
About Elevēo
Elevēo was formed to provide simplified solutions for complex contact center problems. Our products provide only features needed to elevate contact center operations & processes, are built using modern frameworks and cloud native technologies to scale or be hosted anywhere. Elevēo products are birthed from ZOOM International with its rich WFO history, award-winning products, exceptional delivery & reputation for world-class service.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005093/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
